Dr Reddy’s Laboratories (RDY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr. Reddy’s Laboratories has received fines from Germany’s Federal Administration Office for failing to register beneficial owners of its subsidiary companies on time. The fines, totaling over €19,000, were imposed on betapharm Arzneimittel GmbH and Reddy Holding GmbH. Despite this, the company asserts there is no material impact on its financials or operations.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.